Mosquito-borne disease malaria is responsible for around 435,000 deaths per year, and 80-90% of those deaths occur in rural sub-Saharan Africa. However, there was no vaccine until a few years back to prevent this disease. Finally, after 100 years of effort, a vaccine has become a beacon of hope. The World Health Organization (WHO) endorsed a vaccine to fight malaria on October 6, 2021. After conducting pilot vaccination programs in Ghana, Kenya and Malawi, the WHO said it could now be used in children's bodies to prevent moderate to high levels of malaria in sub-Saharan Africa and other regions.  Six years ago, Mosquirix based 'RTS, S' proved to be effective and getting endorsed from WHO is considered a historic event. What is Mosquirix Vaccine? Mosquirix is a malaria vaccine for children aged 6 weeks to 17 months. Additionally, it can also protect against liver infection due to the hepatitis B virus. However, the European Medicines Agency (EMA) suggests not using the vaccine solely for liver infection purposes. Read Covid-19 threatens global progress against malaria: WHO GlaxoSmithKline or GSK invented the vaccine back in 1987. But, they went through many development processes, and today's outcome took more than three decades. However, since the invention Mosquirix has faced some challenges as the protection faded after a few months and required up to four doses. The European Medicine Agency approved this in 2015. In one experiment, Mosquirix was found 30% effective when applied 4 times to children. The World Health Organization has set a target of vaccinating 360,000 children each year in three countries. GSK and Bill & Melinda Gates Foundation have funded about $750 million for the vaccine. Currently, the company is providing 1 crore vaccines free of cost in the ongoing project. Later, they are planning to recoup the money invested through large-scale projects. Read: UN endorses world's 1st malaria vaccine as 'historic moment' Since 2019, around 2.3 million doses have been applied to infants in Kenya, Ghana and Malawi on a large scale, which was coordinated by the WHO. Usage of Mosquirix A 0.5 ml Mosquirix injection is given into the muscle around the shoulder or in the muscle of the thigh. The child will need to take three injections in three months with one month gap between each dose. Further, a fourth dose is also necessary after 18 months of the third dose. However, a prescription is required to get the vaccine. How does Mosquirix RTS, S work? According to the European Medicines Agency's researchers, the active substance in Mosquirix is basically made up of proteins found on the Plasmodium falciparum parasites' surface. When it enters into the body, the immune system takes it as a foreign protein and eventually builds antibodies against them. What does RTS,S stand for? RTS,S is mainly the scientific name of the malaria vaccine candidate. The 'R' means the "central repeat region of Plasmodium (P.) falciparum circumsporozoite protein (CSP)." The 'T' stands for the T-cell epitopes of the CSP, and the 'S' stands for hepatitis B surface antigen (HBsAg). Read Trump's use of malaria drug likely to be welcomed in India